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Summary: Regulatory T cells (Treg) are important regulators of
immune responses. In acute myeloid leukemia (AML) patients
before/after immunotherapy (stem cell transplantation or donor
lymphocyte infusion), their suppressive role can contribute to
suppress severe graft-versus-host reactions, but also to impair
antileukemic reactions. As leukemia-derived dendritic cells (DCleu)
are known to improve the antileukemic functionality of T cells, we
evaluated the composition and development of distinct Treg sub-
types in AML patients (n=12) compared with healthy probands
(n=5) under unstimulated conditions and during stimulation with
DCleu-containing DC (DC) or blast-containing mononuclear cells
(MNC) in 0- to 7-day mixed lymphocyte cultures by flow cytom-
etry. T-cell subgroups in AML patients were correlated with anti-
leukemic functionality before and after DC or MNC stimulation by
functional fluorolysis assays. (1) AML patients’ T cells presented
with significantly higher frequencies of Treg subgroups in unsti-
mulated T cells compared with healthy probands. (2) After 7 days
of DC or MNC stimulation, all Treg subtypes generally increased;
significantly higher frequencies of Treg subtypes were still found in
AML patients. (3) Antileukemic cytotoxicity was achieved in 36%
of T cells after MNC compared with 64% after DC stimulation.
Antileukemic activity after DC but not after MNC stimulation
correlated with significantly lower frequencies of Treg subtypes
(CD8+Treg/Teff/em reg). Furthermore, cut-off values for Treg sub-
populations could be defined, allowing a prediction of antileukemic
response. We demonstrate a crucial role of special Treg subtypes
in the mediation of antileukemic functionality. High CD8+ Treg,
Teff/em reg, and CD39
+ T cells correlated clearly with a reduced
antileukemic activity of T cells. DC stimulation of T cells con-
tributes to overcome impaired antileukemic T-cell reactivity.
Refined analyses in the context of clinical responses to immuno-
therapies and graft versus host reactions are required.
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Acute myeloid leukemia (AML) and myelodysplasticsyndromes (MDS) are clonal disorders of hema-
topoietic stem cells characterized by an impaired cell
differentiation.1 Although up to 70%–80% of patients
younger than 60 years of age achieve a complete remission
with induction therapy, the 2-year survival is only about
46%.2 Despite intensive treatment options such as high-
dose chemotherapy, stem cell transplantation (SCT), and
transfusion of Donor T cells to maintain the antileukemic
function, the rate of relapse or persistence of the disease is
still unsatisfying in patients with AML.
Until now, several soluble or cellular factors are
known that regulate immune mechanisms in healthy indi-
viduals. However, in tumor patients, unbalanced regulatory
mechanisms can contribute to immune escape mechanisms
through which leukemic blasts can escape the killing by the
immune system3: downregulation of HLA class I expression
on tumor cells4 or a defective antigen processing and
expression on tumor cells protect them from elimination by
cytotoxic T lymphocytes (CTL).5 Another escape mecha-
nism uses the disruption of the Fas/FasL system, which
induces apoptosis. Furthermore, soluble factors such as the
immunosuppressive cytokines interleukin (IL)-10 or tumor
growth factor-b, or FasL and 4-1BBL released by T cells,
dendritic cells (DC), or tumor cells can limit the immune
surveillance because of insufficient lymphocyte stimulation
in an inhibitory microenvironment.6,7 Moreover, we and
others have already shown that regulatory soluble factors
produced by host T cells or DC contribute to the regulation
and mediation of antileukemic T-cell function.3 Moreover,
cellular factors such as regulatory T cells (Treg) consisting of
naturally occurring Treg and several subgroups of extra-
thymically activation-induced Treg are known to regulate
immune responses. Treg are classically divided into natu-
rally occurring CD4+CD25+FOXP3+ Treg (nTreg) and
activation-induced Treg (iTreg) appearing after peripheral
antigen stimulation.8 iTreg can belong to CD4
+ and CD8+
T cells, whereas nTreg belong only to CD4
+ T cells, and
form about 1%–2% of the peripheral blood cells.9 From a
clinical point of view, Treg is a 2-edged sword. On the one
hand, Treg physiologically maintain the peripheral immune
tolerance and are able to prevent excessive immune
responses in allergy or autoaggressive immune reactions in
autoimmune diseases, transplantations, or graft-versus-host
disease.10–13 In humans suffering from the IPEX (immune
dysregulation, polyendocrinopathy, enteropathy, X-linked)
syndrome, a mutation in the FOXP3 gene leads to a defi-
ciency of Treg function with severe clinical autoimmune
inflammatory disease.14,15 On the other hand, increased
amounts of Treg can diminish effective antitumor T-cell
responses in patients with cancer.16–18 In the past years,
several attempts have been made to identify specific Treg
markers and to determine the mechanisms of Treg function.
Originally, regulatory T cells were defined as “CD8+
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suppressor T cells” and later on as CD25+CD4+ T cells.19 A
more specific marker was found with the identification of the
transcription factor FOXP3 and its key role in the develop-
ment and function of Treg.
20,21 In addition, surface markers
such as CTLA-4 (CD152+), LAG-3, CD39+ CD73+, and a
low expression of the IL-7 receptor (CD127low) have con-
tributed to a refined definition of Treg. A common dis-
advantage of all of these markers is their potentially
“unspecific” upregulation during the activation of CD4+ T
cells.22 Regarding the function of Treg, 4 basic mechanisms are
postulated for their suppressive function including their
production of inhibitory cytokines such as tumor growth
factor- and IL-10,23,24 their potential of a granzyme B-
dependent cytolysis,25 their potential to downregulate IL-2–
mediated metabolism and immunosuppressive adenosines
generated through the hydrolysis of ATP by the ectoenzymes
CD39+ and CD73+,26,27 and their suppression of DC-medi-
ated T-cell stimulation through the upregulation of CD152+.28
Recent findings of our group showed that an inhib-
itory microenvironment as established by blasts can impair
an antileukemic T-cell response, but can be overcome by
the conversion of leukemic blasts to leukemia-derived DC
(DCleu).
29 Furthermore, we could work out relevant soluble
factors (eg, released cytokines) or cells (eg, amounts of
DCleu and mature DC) that are important and predictive
key players in the successful mediation of antileukemic,
cytotoxic T cells or the clinical response to immunotherapy.
However, there are still cases where no antileukemic func-
tion of T cells after DC stimulation could be achieved.30,31
Thus, the aims of this study were as follows: (1) to evaluate
compositions of several Treg subgroups (eg, CD4
+ Treg,
CD8+ Treg, Tnaive reg) in uncultured peripheral blood-
mononuclear cells from healthy probands and AML
patients; (2) to investigate the development and recruitment
of Treg subgroups during the stimulation of T cells
with DCleu-containing DC (‘DC’) or blast-containing mono-
nuclear cells (‘MNC’) in AML patients compared with healthy
probands; (3) to correlate T-cell expression profiles with the
antileukemic function of ‘DC’-stimulated or ‘MNC’-stimu-
lated T cells in AML patients; and (4) to evaluate potential
antileukemically predictive values of Treg subgroups.
MATERIALS AND METHODS
Sample Collection
After obtaining informed consent, heparinized blood
samples were taken from patients. MNCs were isolated from
whole blood samples by density gradient centrifugation
(Ficoll-Hypaque; Biochrom, Berlin, Germany), and then
washed and suspended in phosphate-buffered saline without
Ca2
+ and Mg2
+ (Biochrom). Cell counts were quantified by
Neubauer counting chambers, frozen with standardized
procedures, and stored in liquid nitrogen until use.
Patients’ Characteristics and Diagnostics
Diagnosis of AML and MDS cases was based on the
French-American-British (FAB) classification. Samples
from 12 patients with AML in acute stages of the disease
were used as sources for DC generation. Sources for T cells
were healthy stem cell donors (“donors,” n=1), patients
before SCT, all of them in active stages of the disease
(“autologous,” n=6), or patients after SCT (“after SCT”,
n=5), with 3 of them in remission and 2 of them at relapse
after SCT (Table 1). Patients’ age at diagnosis was on
average 48 years (range, 5–70 y), and the female to male
ratio was 1:1. Three patients presented with undiffer-
entiated leukemia (M0 n=2, M1 n=2) and 1 with
immature granulocytic leukemia (M2 n=1). Monocytic
leukemia was diagnosed in 6 patients (M4 n=4, M5
n=1). The 1 MDS case was a chronic myelomonocytic
TABLE 1. Patients’ and Samples’ Characteristics
Patients’ Characteristics at the
Time Point of T-cell Preparation
Patients’ Characteristics at the Time Point of DC Generation











Source of T Cells
and the Stage “u” ‘DC’ ‘MNC’
m569 M0 pers. 15, 33, 13, 34, 19 11 CR, after SCT 60 76 63
853 M0 rel. a. SCT 34, 33, 117 50 CR, after SCT +15 75 +10
m761 M1 pers. 34, 117, 15, 65, 2, 7, 53 95 CR, after SCT 30 +150 +55
824 M1/M2 dgn. 7, 13, 34, 117, 123 68 First diagnosis, autologous ND 85 +100
748 M2 dgn. 34, 33, 117, 13, 38 50 First diagnosis, autologous +120 +700 +800
610 M4 pers. rel. 34, 4, 33, 117, 13 80 Stem cell donor, allogenous +400 +220 +260
855 M4 dgn. 13, 33, 34, 65, 117 37 First diagnosis, autologous ND ND ND
880 M4 rel. a. SCT 33, 64, 13, 15, 117, 34, 7 90 Relapse, after SCT* 93 51 9
938 M4 rel. a. SCT 34, 117, 33, 4 74 Relapse, after SCT* 60 77 80
948 M5 dgn. 14, 65, 15, 33 70 First diagnosis, autologous +30 55 +20
887 MDS/CMML pers. 33, 34, 14, 64, 117 8 Persisting disease, autologous* 58 12 12
914 sAML rel. 34, 33, 15, 117 47 Relapse, autologous +800 +250 +350
*T cells harvested at different time points at relapse (patients 880, 938) or during persisting disease (patient 887) and pooled for MLC.
wNegative values: percentual proportions of lysed blasts, positive values: percentual proportions of increased blasts.
AML indicates acute myeloid leukemia; CMML, chronic myelomonocytic leukemias; CR, complete remission; DC, dendritic cells; dgn., diagnosis; IC Bla,
immune cytologically detected blasts; MDS, myelodysplastic syndromes; MLC, mixed lymphocyte cultures; MNC, mononuclear cells; ND, no data; pers. rel.,
persisting relapse; pers., persisting disease; rel. a. SCT, relapse after SCT; rel., relapse; sAML, secondary AML; SCT, stem cell transplantation.
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leukemia (CMML, n=1) and 1 patient suffered from a
secondary AML (sAML n=1) (Table 1). Five healthy
probands served as controls.
Flow cytometric analysis of uncultured MNC frac-
tions was performed to quantify the cellular composition of
MNC in 12 AML patients and in healthy cell samples. The
cellular composition of MNC in AML patients was
3%±2% B cells, 9%±6% T cells, 2%±2% natural
killer cells, 5%±6% monocytes, and 56%±25% blasts.
In cases with aberrant expression of CD19+, CD56+, or
CD14+, B cells, natural killer cells, or monocyte counts,
respectively, could not be quantified.
DC Generation
DCleu-containing DC were generated from AML
patients’ MNC obtained in active stages of the disease (first
diagnosis, persisting disease, relapse before or after SCT)
and afterward used for mixed lymphocyte cultures (MLC)
using stem cell donors’ or patients’ autologous T cells or T
cells after SCT (Table 1).
Thawn MNCs were pipetted in 12-well tissue culture
plates in 1mL Xvivo 15 (Bio Whittaker Europe, Verviers,
Belgium) FCS-free medium. DCs were generated from
blood samples according to a refined strategy culturing cells
in a minimalized assay with 3 DC-generating methods
(MCM-Mimic, Picibanil, Ca-Ionophore, Table 2) in par-
allel, as described by us.31–33
All of the substances used for DC generation are
approved for human treatment.
For the analysis of a successful generation of DC, cells
were quantified by flow cytometry using patient-specific
“blast”-staining antibodies (CD33, CD13, CD15, CD65,
CD34, and CD117) according to diagnostic reports in
combination with DC-staining antibodies (CD1a, CD1b,
CD40, CD80, CD83, CD86, and CD206) as described.34
We defined DC generation as successful if at least >10%
DC and >5% leukemia-derived DC (DCleu) could be
generated in the MNC fraction.32 DCleu were defined by the
coexpression of blast-with DC-markers. The method
resulting in the highest DC count was chosen for quanti-
tative generation of DC.
We generated DC successfully in every given case of
our 12 patient and 5 healthy proband samples according to
procedures already described by members of our group.30,32
AML samples presented with on average 20%±14% DC
(range, 10%–51%) and 6%±2% DCleu (range, 5%–10%)
after cultivation in selected best DC medium for individual
patients. We selected Picibanil, 3 times Ca-Ionophore, and
7 times MCM-mimic.
MLC
As shown in Table 1 CD3+ T cells (later on used as
“effector” T cells) were positively selected (Milteney Bio-
tech, Bergisch-Gladbach, Germany, 1106 cells/well) from
MNC from patients (autologous n=6), from matched
stem cell donors (n=1), or from patients in remission or at
relapse after stem cell transplantation (n=5, Table 1, right
side) and cocultured with “stimulator-cells”: irradiated
(20Gy) AML blast-containing MNC [2.5104 MNC
(T’MNC’)] and in parallel with irradiated DCleu-containing
AML DC [2.5104 DC (T’DC’)] in 1mL RPMI-1640
medium (Biochrom, Berlin, Germany) containing 15%
human serum (PAA) and IL-2 50U/mL (Proleukin R5,
Chiron, Munich, Germany). T-cell stimulation was per-
formed using a cell suspension containing a mixture of
blasts-converted DC (DCleu), blasts, DC, monocytes, and
lymphocytes (‘DC’). Total DC counts in the MLC were
adjusted to 2.5104 DC and T-cell counts adjusted to
1106/well. After 2-fold restimulation with 2.5104 ‘DC’
or ‘MNC’, supplementation of IL-2 (50U/mL), and half
medium exchange on days 3 and 5, cells were harvested on
days 7–8 and the cytotoxicity fluorolysis assay was carried
out. DC (generated from 5 healthy monocytes containing
MNC) or MNC served as healthy “stimulator cells” for
autologous “effector” T cells prepared from these healthy
donors, as described.30,32
Cell Characterization by Flow Cytometry
Flow cytometric analysis was carried out using mono-
clonal mouse antihuman antibodies (moAbs) labeled with
fluorescein isothiocyanate (FITC), phycoerythrin (PE),
tandem Cy7-PE conjugation (PC7), or allophycocyanin
(APC). Antibodies were provided by Immunotech/Beck-
man Coultera, Becton Dickinsonb, Caltagc, Serotechd, and
Invitrogene. As FITC-conjugated moAbs, we used CD1bb,
CD80ab, CD83a, CD86c, CD3a, CD25a, CD39d, CD45ROa,
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pyogenes, PGE2


















AML indicates acute myeloid leukemia; CMML, chronic myelomonocytic leukemias; DC, dendritic cells; MDS, myelodysplastic syndromes; sAML,
secondary AML.
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and CD122d. As PE-conjugated moABs, we used CD80a,
CD83a, CD86bc, CD206a, CD4a, CD8b, CD73b, CD127a,
and CD152a. As PC7-conjugated moABs, we used CD1aa,
CD40c, CD3a, CD4a, CCR7b, and 7AAD. CD34a c,
CD117a, CD33a, CD1aa, CD40c, CD206a CD3a, CD8b,
CD25e, CD45ROe, CD69b, and CD71b were used as APC-
conjugated moAbs.
For analysis and quantification of lymphocytes,
monocytes, and leukemic blasts before culture, the total
MNC fraction was gated. Proportions of positive events in
defined gates compared with the isotype controls were
calculated using the Cell Quest software. Quantification
and characterization of DC and DCleu were performed by
flow cytometry according to our gating strategy already
described by former groups.30–34 To quantify and charac-
terize the several T-cell subpopulations, we defined a
“lympho-gate” surrounding lymphocytes and monocytes.
T-cell subgroups were defined by antigen coexpression
before and after ‘MNC’ or ‘DC’ stimulation as shown
in Table 3. Flow cytometric analyses were carried out on
days 0, 1, 3, 5, and 7 followed by a functional cytotoxic
fluorolysis assay on days 7 or 8 as described below.
Cytotoxicity Fluorolysis Assay
The lytic activity of effector T cells was measured by
a fluorolysis assay by counting viable blast target cells,
labeled with specific fluorochrome antibodies, before and
after effector cell contact as described.30 ‘DC’-stimulated or
‘MNC’-stimulated T cells from healthy matched donors
(n=1), from AML patients (autologous n=5), or from
AML patients after SCT (after SCT n=5) and unstimu-
lated T cells were cocultured with thawn blasts as target
cells for 4 or 24 hours, as described. Before culture, blast-
target cells were stained for 15 minutes with 2 FITC and/or
PE-conjugated blast-specific antibodies and subsequently
cocultured with effector cells. As a control, target and
effector cells were cultured separately and mingled with
T cells shortly before FACS analysis. To evaluate the
amount of viable (7AAD) target cells and to quantify the
cell loss after 24 hours of incubation, cells were harvested,
washed in phosphate-buffered saline, and resuspended in a
FACS flow solution containing 7AAD (BD, Biosciences
Pharmingen) and a defined number of fluorospheres beads
(Becton Dickinson, BD, Heidelberg, Germany). Viable cells
were gated in an SSC/7AAD gate, and viable cells co-
expressing the patient-specific blast phenotype were quan-
tified later by taking into account defined counts of
calibration beads as described. Cells were analyzed in a
FACS Calibur Flow Cytometer using the CELL Quest
software (Becton Dickinson). The percentage of lysis was
defined as the difference between proportions of viable
blasts before and after effector cell contact. Results are
given in Table 1.
Statistical Methods
Means, SDs, and results with the 2-tailed t test were
evaluated with a personal computer using Excel2007
(Microsoft). Differences were considered as significant if the
P-value was <0.05.
RESULTS
We wanted to enlighten the development, activation,
proliferation, and differentiation of T cells before and
especially after ‘MNC’ or ‘DC’ stimulation in AML
patients and healthy probands with special focus on the role
of regulatory T cells and Treg subtypes (as given in Table 3)
in the mediation of antileukemic activities of ‘MNC’-
stimulated, ‘DC’-stimulated, or unstimulated T cells.
‘DC’ Stimulation Leads to Alteration in
T-cell Profiles
We and others have already demonstrated the variable
blast-lytical outcome of T cells after ‘MNC’ or ‘DC’ stim-
ulation.30 We compared the expression of several T-cell
markers (as listed in Table 2) on unstimulated T cells (day
0) and after stimulation (day 7) in MLC. To prevent any
unwanted ‘MNC’ or ‘DC’ stimulation of T cells, measure-
ments on day 0 were carried out “on ice.”
TABLE 3. Subtypes of T Cells and Treg as Evaluated by Flow Cytometry
Names of T-cell Subgroups Short Text Form Surface Marker Combination
CD3+ T cells CD3+ T cells CD3+
CD4+-expressing T cells CD4+ T cells CD4+CD3+
CD8+-expressing T cells CD8+ T cells CD8+CD3+
Regulatory T cells Treg
IL-2-R+IL-7-Rlow-expressing CD8+ T cells CD8+ Treg CD8
+CD25++CD127low
IL-2-R+IL-7-Rlow-expressing CD4+ T cells CD4+ Treg CD4
+CD25++CD127low
IL-2-R+IL-7-RlowCCR7CD45RO T cells Tnaive reg CD25
++CD127lowCD194CD45RO
IL-2-R+IL-7-RlowCCR7CD45RO+ T cells Teff/em reg CD25
++CD127lowCCR7CD45RO+






IL7-Rlow Ecto-50-Nucleotidase-expressing T cells CD73+ Treg CD73
+
CTLA-4+ T cells CD152+ Treg CD152
+ CD3+
Activated T cells
IL-2-R+ T cells CD122+ T cells CD122+CD3+
CD40L+ T cells CD154+ T cells CD152+CD3+
IL-2-R+ CD4+ T cells CD25+CD4+ T cells CD25+CD4+
IL-2-R+ CD8+ T cells CD25+CD8+ T cells CD25+CD8+
IL-7-R+ CD4+ T cells CD127+CD4+ T cells CD127+CD4+
IL-7-R+ CD8+ T cells CD127+CD8+ T cells CD127+CD8+
Proliferating T cells
Type II C-type lectin+ T cells CD69+ T cells CD69+CD3+
Transferrin-R+ T cells CD71+ T cells CD71+CD3+
Schick et al J Immunother  Volume 36, Number 4, May 2013
226 | www.immunotherapy-journal.com r 2013 Lippincott Williams & Wilkins
Profiles of Uncultured T Cells From AML Patients
Compared With Healthy Probands
AML Patients Show Significantly Lower Levels of
Both CD127+CD4+ and CD127+CD8+ T Cells
Before DC or MNC Stimulation
We studied the expression of activation and proliferation
markers on uncultured T cells from AML patients and from
healthy probands. Low amounts of proliferating or activated T
cells (CD3+ T cells expressing CD69, CD71, and CD122 or
CD4+/CD8+T cells expressing CD25) were found on unstimu-
lated T cells (d0) in the MLC of healthy donors and AML
patients (Fig. 1A). However, healthy probands showed sig-
nificantly higher levels of CD127+CD4+ (93%±7% vs.
65%±21%) and CD127+CD8+ (86%±10% vs. 52%±
17%) T cells compared with AML patients (P<0.005, Fig. 1A).
In summary, this means that low amounts of pro-
liferating T cells were found in unstimulated T cells from
healthy donors or AML patients, but significantly higher
proportions of CD4+/CD8+ T cells expressed CD127 in
healthy compared with AML donors.
AML Patients Present With Significantly Higher
Levels of Several Treg Subgroups Before ‘DC’ or
‘MNC’ Stimulation
We compared the expression of common regulatory
cell markers on uncultured T cells of AML patients and
healthy probands.
Comparable amounts of unstimulated (d0) CD3+
T cells expressing CD152 or CD4+ T cells expressing CD39
(with or without CD25/CD127 expression) were found in
healthy probands or AML patients (Fig. 1B, upper part).
However, healthy probands showed significantly lower
amounts of CD4+ Treg in CD4
+ T cells (11%±5% vs.
29%±11%, P<0.005) or CD8+ Treg in CD8
+
T cells (4%±2% vs. 14%±9%, P<0.005) or CD39+
cells in MLC fractions (10%±6% vs. 25%±6%,
P<0.005) compared with AML patients. In contrast, we
found significantly higher amounts of CD73+ cells in MLC
in healthy probands compared with AML patients
(33%±5% vs. 19%±11%, P<0.005, Fig. 1B, upper part).
Furthermore we found significantly lower amounts of all
Treg subsets in unstimulated cell fractions in healthy probands
compared with AML patients: Tnaive reg in MLC (1%±1%
vs. 4%±4%, P<0.05), Tnaive reg in Tnaive, (12%±17% vs.
28%±17%, P<0.05), Teff/em reg in MLC (5%±3% vs.
10%±7%, P<0.05), Teff/em reg in Teff/em (9%±7%
vs. 19%±9%, P<0.005), Tcm reg in MLC (1%±1% vs.
4%±2% P<0.005), and Tcm reg in Tcm (17%±14% vs.
31%±13%, P<0.05) (Fig. 1B, lower part).
In summary, we found significantly lower frequencies
of several Treg subgroups in unstimulated T cells in healthy
probands compared with AML patients.
Profiles of ‘MNC’-stimulated Versus ‘DC’-
stimulated T Cells After 7 Days of Culture in MLC
in Cases With AML or in Healthy Probands
AML Patients Show Significantly Lower Levels of
CD127+CD4+ and CD127+CD8+ T Cells After ‘DC’
or ‘MNC’ Stimulation Compared With Healthy
Probands
We compared the expression of common regulatory
cell markers on T cells from AML patients and healthy
probands after stimulation with ‘MNC’ or ‘DC’, respec-
tively (Fig. 2A).
In the AML patients’ cohort, after 7 days with ‘DC’
stimulation, comparable, although lower, amounts of CD3+ T
cells coexpressed CD69+, CD71+, and CD122+ compared
with healthy donors. Moreover, comparable amounts
of both CD4+ and CD8+ T cells coexpressing CD25 were
found (Fig. 2A). However, compared with AML patients,
healthy probands showed significantly higher levels of
CD127+CD4+ (78%±20% vs. 26%±19%, P<0.05) and
CD127+CD8+ T cells on day 7 (62%±27% vs. 17%±14%,
P<0.05, Fig. 2A). After 7 days of ‘MNC’ stimulation, similar
expression patterns could be observed (data not shown).
AML Patients Present With Significantly
Higher Levels of Tcm reg and Teff/em reg After ‘DC’ or
‘MNC’ Stimulation Compared With Healthy Probands
We compared the expression of various regulatory cell
markers on T cells from AML patients and healthy probands
after stimulation with ‘MNC’ or ‘DC’, respectively (Fig. 2B).
Concerning the expression of CD73+, CD152+,
CD39+CD4+, and CD39+CD25++CD127low T cells, no sig-
nificant differences between AML patients and healthy pro-
bands could be observed after 7 days with ‘DC’ stimulation
(Fig. 2B). Tendentially, healthy probands showed lower
amounts of CD4+Treg (referred to CD4
+ cells) and CD8+ Treg
(referred to CD8+ cells) compared with AML patients
(P<0.1) (Fig. 2B, upper part). However, compared
with AML samples, healthy probands presented with
significantly lower amounts of Tcm reg (26%±8% vs. 58%±
21%, P<0.005) and Teff/em reg (33%±14% vs. 59%±
16%, P<0.05) and tendentially lower amounts of Tnaive reg
(53%±31% vs. 78%±22%, Pr0.1, Fig. 2B, lower part)
after 7 days of ‘DC’ stimulation. Values after 7 days of ‘MNC’
stimulation in AML patients and healthy probands were
comparable to values after ‘DC’ stimulation (data not shown).
In summary, we still found significantly higher levels
of Treg subtypes in AML patients compared with healthy
probands on day 7.
Kinetic Profiles of Surface Markers on T Cells in the
Time Course of ‘DC’ or ‘MNC’ Stimulation (Day 0–7)
We examined the kinetic development of surface marker
profiles, performed measurements on days 0, 1, 3, 5, and 7,
and compared statistical profiles of day 0 and 7 (Fig. 3).
Expression Profiles of Activation and Proliferation Are
Comparable in AML Patients and Healthy Probands
Proportions of CD25+ T cells stayed rather constant
during ‘DC’ stimulation between day 0 and day 7 in both
groups (Fig. 3A). In general (with the exception of CD127),
T cells from healthy probands showed a similar kinetic
development during ‘DC’ stimulation compared with AML
patients. As shown in Fig. 3A, the kinetics of healthy probands
showed no significant decrease in CD127+ T cells, whereas the
expression on CD4+ T cells decreased significantly from
63%±23% to 26%±19% in AML patients (P<0.005)
between day 0 and 7. We could demonstrate a significant
increase in CD69+ T cells in AML patients (2%±2% to
18%±20%, P<0.05) and healthy probands (6%±7%
to 21%±9%, P<0.05) between day 0 and 7 of ‘DC’ stim-
ulation (P<0.05, Fig. 3A). CD71+ T cells of AML patients
(8%±9% to 28%±19%, P<0.05) and healthy probands
(15%±15% to 39%±22%, P<0.1) and CD122+ T cells of
AML patients (4%±2% to 12%±9%, P<0.05) and healthy
probands (4%±2% to 12%±8%, P<0.1) showed a sig-
nificant continuous increase, reaching high values on days 3–5.
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During stimulation with ‘MNC’, we could demonstrate
an analogous kinetic development as with ‘DC’ stimulations
in healthy and AML samples (data not shown).
In summary, we could show that after 7 days of
stimulation with ‘DC’ or ‘MNC’, all 17 MLC presented
with an increase in immunologic activation markers.
Compared with day 0, AML patients and healthy probands
showed a significant upregulation of CD69+, CD71+, and
CD122+ T cells and a significant downregulation of
CD127+ T cells (only in AML) after ‘DC’ stimulation and
after ‘MNC’ stimulation (data not shown).
AML Patients and Healthy Probands Show a
Continuous Increase in Treg Subgroups
Similarly, no significant changes in the proportion of
CD152+ T cells between d0 and d7 were seen in AML patients
and healthy probands (Fig. 3B). A significant increase in the
proportion of T-cell subtypes between d0 and d7 was found in
FIGURE 1. Profiles of uncultured T cells from AML patients versus healthy probands on day 0. Unstimulated T cells before MLC with
‘DC’ or ‘MNC’ of AML or healthy samples were stained with different fluorochrome-labeled antibodies, and subpopulations charac-
terizing activation and proliferation (A) or regulation (B) were specifically gated and quantified. AML indicates acute myeloid leukemia;
DC, dendritic cells; MLC, mixed lymphocyte cultures; MNC, mononuclear cells.
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AML patients and in healthy probands for Tnaive reg (AML:
32%±20% to 78%±22%, P<0.005; healthy: 13%±22%
to 53%±31%, P<0.05), Tcm (AML: 35%±14% to
58%±21%, P<0.05; healthy: 18%±17% to 26%±8%,
P<0.1), Teff/em reg (AML: 20%±10% to 59%±16%,
P<0.005; healthy: 11%±8% to 33%±14%, P<0.05),
CD8+ Treg (AML: 15%±9% to 53%±22%, P<0.005;
healthy: 4%±2% to 33%±19%, P<0.05), and CD4+ Treg
(AML: 31%±11% to 50%±16%, P<0.005; healthy:
12%±6% to 35%±15%, P<0.05). Regarding the
ectoenzymes CD39+ and CD73+, we could detect a con-
tinuous and tendentially significant decrease in CD73+ cells in
AML patients and a significant decrease in healthy probands
(AML: 19%±11% to 13%±08%, P<0.1; healthy:
33%±5% to 20%±8%, P<0.05). CD39+ cells,
CD39+CD4+, or CD39+CD127lowCD25++CD4+ in CD4+
T cells showed no significant increase in AML patients.
However, as shown in Fig. 3B, in healthy probands, we found
FIGURE 2. Profiles of ‘DC’-stimulated T cells from AML patients versus healthy probands on day 7. T cells after MLC with ‘DC’ of AML or
healthy samples were stained with different fluorochrome-labeled antibodies, and subpopulations characterizing activation and pro-
liferation (A) or regulation (B) were specifically gated and quantified. AML indicates acute myeloid leukemia; DC, dendritic cells; MLC,
mixed lymphocyte cultures.
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a significant and continuous increase in CD39+ cells (10%±6%
to 29%±13%, P<0.05) and CD39+CD25++CD127lowCD4+
cells (8%±8% to 28%±23%, P<0.1).
After ‘MNC’ stimulation, we could demonstrate an
analogous kinetic development (data not shown).
In summary, all subtypes of Treg increased significantly
after ‘DC’ or ‘MNC’ stimulation among AML patients and
healthy probands. In AML patients, CD39+ Treg showed no
increase after 7 days of ‘DC’ or ‘MNC’ stimulation, whereas a
tendentially significant increase in CD39+ Treg and a significant
increase in CD39+ cells was observed after ‘DC’ stimulation in
healthy probands. We could not detect any significant differ-
ences in the pattern of regulatory T cells after ‘DC’ or ‘MNC’
stimulation in AML patients and in healthy probands.
Correlation of T-cell Expression Profiles With the
Antileukemic Function of ‘MNC’-stimulated, ‘DC’-
stimulated, or Unstimulated T Cells in AML Cases
We have already demonstrated that stimulation with
DCleu improves the antileukemic function of T cells. Thus,
FIGURE 3. Kinetic profiles of surface markers on T cells from AML patients versus healthy probands (in the time course of ‘DC’
stimulation). Expression profiles of activation and proliferation markers (A) and regulation markers (B) in the course of ‘DC’ stimulation
in healthy (left side) or AML samples (right side) after specific gating of T-cell subtypes are given. AML indicates acute myeloid leukemia;
DC, dendritic cells.
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we wanted to examine the potential differences of surface
marker expression concerning the activation and regulation
of T cells in the context of the antileukemic function of
‘DC’-stimulated/‘MNC’-stimulated T cells. We subdivided
our cases into those that gained lytic activity (“lysis”) and
those that were not able to lyse blasts (“nonlysis”) after
‘DC’ or ‘MNC’ stimulation and compared the surface
marker profiles regarding the expression of activation,
proliferation, and regulation markers on “MNC-stim-
ulated,” “DC-stimulated,” or unstimulated T cells.
Functional assays showed that ‘MNC’ stimulation
induced antileukemic cytotoxicity in 4 of 11 cases (36%)
compared with 7 of 11 cases (64%) after ‘DC’ stimulation.
Unstimulated T cells showed lytic activity in 5 of 10 cases
(50%). Unstimulated T cells showed an average lytic effi-
ciency of 60% of blasts (range, 30%–93%), ‘MNC’-stimu-
lated T cells of 41% (range, 9%–80%), and ‘DC’-stimulated
T cells of 62% (range, 12%–85%) of blasts. Cases with lysis
after ‘DC’ stimulation consisted of T cells after SCT (n=4)
and autologous T cells (n=3). Cases with lysis after ‘MNC’
stimulation were T cells from patients after SCT (n=3) and
in autologous T cells in 1 case. T-cell sources of cases with
lysis of unstimulated T cells were T cells after SCT (n=4)
and in 1 case autologous T cells. Results of antileukemic
activity in individual cases are given in Table 1 (right side).
T-cell Profiles of T Cells Before Stimulation With
‘DC’ or ‘MNC’ in AML Cases
Expression Profiles of Activation and Proliferation
Markers on T Cells Before ‘DC’ or ‘MNC’
Stimulation in Lysis and Nonlysis Groups of AML
Cases Do Not Differ
On day 0 before ‘DC’ stimulation, we found no sig-
nificant differences between the lytically active and non-
active groups regarding the expression profiles of activation
and proliferation markers (Fig. 4A, left side).
Tendentially Lower Proportions of CD8+ Treg in
the Lysis Group Before ‘DC’ But Not Before ‘MNC’
Stimulation
On day 0 before ‘DC’ stimulation, we found no sig-
nificant differences between the lytically active and nonactive
groups regarding the expression profiles of CD152+, CD4+
Treg, CD39
+, CD73+, CD39+CD4+, CD39+CD25++
CD127low, Tnaive reg, Teff/em reg, and Tcm reg (Fig. 4B, left side).
However, we found tendentially lower proportions of CD8+
Treg (referred to CD8
+ cells) before ‘DC’ stimulation in the
later-on lysis group compared with the nonlysis group
(10%±3% vs. 23%±12% Pr0.1; Fig. 4B, left side).
Before ‘MNC’ stimulation, we could not detect any
significant differences in the levels of any regulatory sub-
groups between the later on lysis and nonlysis groups (data
not shown).
T-cell Profiles After ‘MNC’ or ‘DC’ Stimulation in
AML Cases
Expression Profiles of Activation and Proliferation
Markers Do Not Show Significant Differences After
‘DC’ or ‘MNC’ Stimulation in AML Cases
No significant differences in proportions of activated
T cells (positive for CD69+, C71+, CD25+, CD122+, and
CD127+) were found between the lytically active and non-
active groups after ‘DC’ stimulation (Fig.4A, right side).
The Lysis Group Presents With Significantly Lower
Amounts of CD8+ Treg and Teff/em reg After ‘DC’ But
Not After ‘MNC’ Stimulation in AML Cases
No significant differences in proportions of regulatory
T-cell subtypes were found in proportions of the following
markers in the lytically active compared with the nonactive
group after DC stimulation (Fig. 4A, right side): CD152+
T cells, CD4+Treg, CD73
+, CD39+, or CD39+CD25++
CD127low, T cells, and Tnaive reg and Tcm reg T cells. Tenden-
tially, significantly lower proportions of CD39+CD4+
T cells (referred to as CD4+ cells) were found in cases with
lysis than in cases without lysis after DC stimulation (29%±
14% compared with 44%±13%, Pr0.1). Significantly lower
proportions of CD8+ Treg (referred to as CD8
+ cells,
45%±15% compared with 76%±13%, P<0.05) and
Teff/em reg (referred to as Teff/em; 49%±12% compared with
75%±7%, P<0.005) were found in the lysis compared with
the nonlysis group after ‘DC’ stimulation (Fig. 4B, right side).
It is interesting to note that these correlations between
expression profiles concerning regulatory T cells and anti-
leukemic functionality were not detectable after ‘MNC’
stimulation.
In summary, we found that low proportions of Treg
subpopulations (CD8+ Treg, Teff/em reg, and CD39
+ CD4+)
in unstimulated and even more in ‘DC’-stimulated cell
fractions went along with good antileukemic ex vivo
activity (Fig. 4B).
Cut-off Values of Treg Subpopulations Contribute
to Predict the Antileukemic Reactivity of
Unstimulated and Even More of ‘DC’-stimulated
T Cells in AML Cases
To gain a better prediction of the antileukemic behavior
of ‘DC’-stimulated or unstimulated T cells, we subgrouped our
cases according to their antileukemic function and evaluated
predictive cut-off values. These values could be defined for the
following regulatory subgroups (before or after ‘DC’ stim-
ulation): CD8+ Treg (referred to as CD8
+ cells), Teff/em reg
(referred to as Teff/em), Tcm reg (referred to as Tcm), and
Tnaive reg (referred to as Tnaive, Fig. 5). In detail, we could show
that cases with <60% of CD8+ Treg in all CD8
+ cells,
those with <60% of Teff/em reg in all Teff/em cells, and those
with <70% of Tcm reg in all Tcm cells showed an 80%–100%
antileukemic T-cell activity. Cases with higher proportions of
these regulatory T cells had a high probability to belong to the
nonlytic group (range, 67%–100%). These cut-off values
became more distinctive after ‘DC’ stimulation compared with
unstimulated samples and could not be defined after ‘MNC’
stimulation. Moreover, we could not define any cut-off values
regarding the proportions of the activation or the proliferation
markers expressed.
Furthermore, we tried to compare these cellular findings
with the patients’ clinical outcomes. Five of our 12 patients
received immunotherapy, of whom 3 patients did not respond,
1 responded, and 1 died of SCT-related complications. The
patient responding to immunotherapy had lower proportions
of CD8+ Treg and Teff/em reg before stimulation and higher
proportions of Tnaive reg before and after DC stimulation
compared with the nonresponders (data not shown).
In summary, our findings show that cases with
an antileukemic function presented in general with lower
amounts of Treg subgroups (CD8
+ Treg and Teff/em reg) in
unstimulated and even more in ‘DC’-stimulated cases.
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DISCUSSION
Regulatory T cells (iTreg) and their subgroups play a
critical role in the mediation of immune responses. With
respect to AML patients, the role of Treg is of special
interest: on the one hand, the suppressive role of Treg
and their ability to suppress lethal graft-versus-host
disease could be demonstrated,35–37 but on the other, high
Treg counts after SCT, respectively, after adoptive Treg-cell
transfer could be correlated with reduced graft-versus-
leukemia effects.38–40 Recently, our research group
demonstrated that the conversion of leukemic blasts into
leukemia-derived DC (DCleu), being effective professional
antigen-presenting cells by inducing activation, pro-
liferation, and differentiation of naı̈ve T cells into different
FIGURE 4. Correlation of T-cell subgroups with the antileukemic function of ‘DC’-stimulated T cells in AML cases. Expression profiles of
activation and proliferation markers (A) or regulation markers (B) on T cells from AML patients before (left side) or after ‘DC’ stimulation
(right side) are given with cases subdivided into those with or without antileukemic functionality. AML indicates acute myeloid
leukemia; DC, dendritic cells.
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effector T cells, can improve the mediation of an anti-
leukemic T-cell response and provides a good ex vivo model
to study stimulatory influences on T cells.30 To gain new
insights into the role of Treg and the mediation of anti-
leukemic T-cell responses, we investigated the profile of
unstimulated T cells, with ex vivo DCleu containing DC
(‘DC’) or leukemic blasts containing ‘MNC’-stimulated T
cells in AML patients compared with healthy probands.
Finally, we correlated the Treg distribution with the medi-
ation of an effective antileukemic T-cell cytotoxicity (lysis
vs. nonlysis).
First of all, the present study confirms our former find-
ings, showing that ‘DC’-stimulated T cells improve the medi-
ation of an antileukemic T-cell response compared with
‘MNC’-stimulated T cells. The present study verified that
unstimulated T cells showed a reduced induction of anti-
leukemic cytotoxicity compared with ‘DC’-stimulated T cells,
but a higher percentage of antileukemic function compared
with ‘MNC’-stimulated T cells.30,31 These findings contribute
to the assumption that the inhibitory microenvironment
induced by blasts could be abolished after blast conversion to
DCleu.
29
General Activation and Proliferation After ‘DC’
or ‘MNC’ Stimulation
T-cell stimulation with ‘DC’ or ‘MNC’ leads to a
general T-cell activation and proliferation.31 During ‘DC’
or ‘MNC’ stimulation, we could observe an upregulation of
FIGURE 5. Cut-off values of Treg subpopulations contribute to the prediction of the antileukemic reactivity of unstimulated and even
more of ‘DC’-stimulated T cells in AML cases. Proportions of selected Treg subtypes before (left side) or after ‘DC’ stimulation (right side)
that correlate with the lytic or the nonlytic function of T cells are given. AML indicates acute myeloid leukemia; DC, dendritic cells.
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activation and proliferation surface markers. According to
former studies, we also found the typical pattern of an early
upregulation of CD69+ already on day 1 and a delayed
upregulation of the proliferation marker CD71+, reaching
the maximum expression on T cells on day 5.41,42 The
surface expression of CD25+ already had a relatively high
base level on unstimulated T cells compared with other
surface markers and showed no significant upregulation on
activated T cells during the whole time course. Nguyen and
colleagues postulated the coexpression of CD71+ and
CD25+ as reliable markers for T-cell proliferation. Our
data suggest the single expression of CD71+ as the most
reliable marker to evaluate T-cell proliferation. As already
described, we could observe a downregulation of CD127+,
the IL-7-receptor, during T-cell proliferation.43,44 Our
observation of a significantly higher surface expression of
CD127+ on unstimulated T cells in healthy probands
compared with AML patients might express the higher
proliferation potential of healthy T cells compared with
T cells in AML patients.
CD4+CD25++CD127low Treg Instead of FOXP3
+ Treg
Originally, Treg were defined through the expression of
the intracellular transcriptional factor FOXP3+, which is
an important regulator of the development and function of
Treg and is classified as one of the most reliable Treg
markers.21,45 However, several studies described the exis-
tence of suppressive T cells not expressing FOXP3+.46
Several studies have demonstrated a high correlation
between the expression of FOXP3+ and the low surface
expression of the IL-7 receptor a chain (CD127low) on
Treg.
47–49 It is interesting to note that Hartigan-O’Connor
et al49 found robustly suppressive CD25+ CD127low T cells
despite the low expression of FOXP3. Therefore, we
decided to use CD127low as the Treg marker in our model to
address FOXP3+ and FOXP3-Treg. Moreover, by focusing
on extracellular surface markers, our methodological pro-
cedures were not impaired through permeabilization
techniques.
High Counts of Distinct Treg Subgroups Correlate
With Cancer
It has been demonstrated that increased frequencies of
Treg or a loss of Treg-mediated immune tolerance correlates
with several solid cancers and hematologic diseases.40 In the
present study, we demonstrated that AML patients presented
with significantly higher frequencies of several Treg subgroups
in unstimulated T cells compared with healthy probands,
correlating with the findings of former studies.17,50 Shenghui
et al51 have already shown that an elevated frequency of Treg in
the peripheral blood and bone marrow is associated with a
poor prognosis in AML patients. However, although most of
these studies were restricted to the well-investigated
CD4+CD25highFOXP3+Treg, there have been some recent
reports of other subpopulations of clinically interesting regu-
latory T cells. Beside CD4+ Treg, recently, the existence of
cytotoxic CD4+T cells was demonstrated, contradicting the
paradigm of CD4+ T-helper cells and CD8+ cytotoxic T cells
(Steger B, unpublished data, 2012). Recently, more inves-
tigations have been conducted to determine the suppressive
role of the less well-described CD8+ Treg population in can-
cer.52,53 There is already increasing evidence indicating that
CD8+ Treg might accumulate in the tumor microenvironment in
solid tumor diseases such as prostate or ovarian cancer.53–55
Moreover, Chaput et al56 demonstrated significantly higher
proportions of circulating CD8+ Treg in the peripheral blood of
colon cancer patients compared with healthy probands.
Actually, less is known about circulating CD8+ Treg in AML
patients’ peripheral blood.
Recently, several working groups have described Treg
subgroups, consisting of phenotypically and functionally
distinct subtypes such as naı̈ve Treg and effector Treg,
because of their ability to differentiate into effector/memory
cells after antigen contact.46,57–59 In the present study, we
could demonstrate higher frequencies of CD4+ Treg and
CD8+ Treg and also of Tnaive reg, Tcm reg, and Teff/em reg in
AML patients compared with healthy probands. These
findings implicate that regulatory and effector T-cell subsets
have a greater plasticity than originally thought.
Another Treg subgroup is defined to mediate the sup-
pressive mechanism of adenosine produced through the
ectoenzymes CD39+ (ectonucleoside triphosphate diphos-
phohydrolase) and CD73+ (ecto-50-nucleotidase 1), which
catalyze the sequential hydrolysis of ATP/ADP.60 In humans,
the expression of CD39+ is found on B cells, leukemic blasts,
and T cells and Treg with restriction to Teff/em reg.
26 Szczepanski
et al17 have shown that Treg in AML patients express CD39
+
and CD73+ and consequently hydrolyze ATP more efficiently
than Treg in healthy probands. In unstimulated T cells, we
found a higher expression frequency of CD39+ and a lower
expression frequency of CD73+ in AML patients compared
with healthy probands as most of our patients were studied
during chemotherapeutic treatment. These data indicate that
because of tumor lysis effects, free nucleosides influence
the surface expression frequencies of CD39+ and CD73+ in
AML patients compared with healthy probands. Because
of the different expression frequencies, we recommend the
monitoring of CD39+ Treg only in AML patients without high
levels of free nucleotides (due to chemotherapeutic
intervention).
CTLA4 (CD152+) mediates suppression by binding to
CD80+ and CD86+ on DC, through which these
costimulatory surface molecules for T-cell activation are
reduced on DC.61 We could detect neither a significant
difference in the surface expression profile of CD152+ on
healthy Treg compared with the Treg of AML patients nor
an increase of this surface marker during DC or MNC
stimulation. These findings suggest that in this setting,
CTLA-4 does not play a crucial role. Similar findings have
been reported formerly.62
Kinetic Development of Treg Subgroups Under
Stimulation
The common problem of all Treg markers is their
general upregulation on activated T cells, which reduces
their specific correlation to Treg. Recent publications have
also shown a general in vitro expansion of CD4+ Treg by
‘DC’ stimulation during MLC.63 Mahic et al64 demon-
strated an increase in CD8+ Treg by continuous antigen
stimulation. During ‘DC’ or ‘MNC’ stimulation, we found
a continuous increase in most of the Treg subgroups in
AML patients and in healthy probands. After stimulation
by MLC, we still found significantly higher levels of Tcm reg
and Teff/em reg and tendentially higher levels of CD4
+ and
CD8+ Treg in AML patients compared with healthy
probands.
Previous data of our group showed an upregulation of
CD39+ during ex vivo of healthy T cells with nucleosides,
whereas the expression of CD73+ was downregulated
(Weiler M, unpublished data). During ‘DC’ and ‘MNC’
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stimulation, in the present study, we also observed an
upregulation of CD39+ and a downregulation of CD73+ in
healthy probands. It is interesting to note that AML
patients did not show significant changes in the expression
frequencies of CD39+ and CD73+ during stimulation,
probably due to a high expression of CD39+ and a low
expression of CD73+ antigens before culture.
The Antileukemic Functionality Correlates With
Frequencies of Treg
Our data showed that an antileukemic T-cell response
was achieved in 60% of AML cases after ‘DC’ stimulation
compared with 40% after ‘MNC’ stimulation. Con-
sequently, ‘DC’ stimulation seems to be an option to
reverse T-cell anergy and to reestablish an antileukemic T-
cell response, as already shown by our group.29,30 In the
context of the present study, we could correlate differences
in Treg profiles with the antileukemic functionality after
‘DC’, but not after ‘MNC’ stimulation. Moreover, ex vivo
cut-off values predicting the antileukemic functionality
were definable. The present study could demonstrate sig-
nificantly higher proportions of CD8+Treg and Teff/em reg in
the nonlysis group compared with the lysis group after ‘DC’
stimulation. The expression frequencies of these Treg sub-
groups in the lysis group were comparable to the expression
frequencies in our healthy probands. Surprisingly, we could
not detect any correlations in the proportions of CD4+ Treg
with the lysis or the nonlysis group.
CONCLUSIONS
In summary, our results provide new insights into the
cellular profiles and the antileukemic T-cell functionality of
Treg. Our findings suggest a crucial role of CD8
+Treg and
Teff/em reg in the mediation of the immune escape in AML
patients. Moreover, we showed that frequencies of dis-
tinctly decreased levels of Treg subtypes correlate with the
reestablishment of the antileukemic functionality in a sig-
nificant proportion of patients. We could even define cut-off
values for Treg subtypes, which allow an estimation of the
lytic potential of individual patients’ T cells. CD39+ and
CD73+ expression on Treg subgroups have to be discussed
critically in patients with a high cellular turnover because of
chemotherapy.
From a clinical point of view, our data recommend the
monitoring of the distinct Treg subgroups (CD8
+ Treg, and
Teff/em reg) and defining cut-off values in vivo. In the context
of immunotherapeutic strategies, further experiments are
necessary to learn about mechanisms involved in the sup-
pression of antileukemic graft-versus-leukemia reactions
and to create strategies to manipulate Treg subtypes (eg, by
abolishing an inhibitory blast microenvironment in vivo) or
to learn about mechanisms responsible for diminished graft
versus host reactions and to manipulate them (eg, by
elimination of autoreactive T cells).
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